决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Immune signature and pathways investigation of adrenal gland diffuse large B-cell lymphoma.
弥漫大B细胞淋巴瘤(DLBCL)约占所有非霍奇金淋巴瘤病例的30-40%。
弥漫性大B细胞淋巴瘤(DLBCL)约占所有非霍奇金淋巴瘤病例的30-40%。已有报道指出DLBCL可发生于淋巴结、胃、胃肠道或皮肤等器官。然而,肾上腺DLBCL尚未得到充分探索。我们对来自肾上腺的十例DLBCL样本进行了RNA测序,整合分析了来自多个器官的DLBCL RNA数据,定义了肾上腺DLBCL的新亚型并探索了其分子特征。与其他器官相比,我们观察到了肾上腺DLBCL的特殊表达模式和微环境免疫评分。预测自然杀伤T细胞在肾上腺DLBCL中显著富集,发现经典癌症通路如programmed death protein 1信号通路、肿瘤坏死因子信号通路和肽抗原结合通路与肾上腺DLBCL相关。进一步分析通过RNA表达模式定义了两种不同的肾上腺DLBCL亚型。我们的研究揭示了特殊的表达特征,定义了肾上腺DLBCL的分子亚型。这些结果扩展了器官相关DLBCL数据,提供了关于肾上腺DLBCL表达谱的新知识。
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30-40% of all non-Hodgkin lymphoma cases. Organs located DLBCL such as lymph node, stomach, gastrointestinal tract, or skin were reported. However, the adrenal gland DLBCL was not been well explored. We performed RNA sequencing of ten DLBCL samples from adrenal gland, integrated analyzed DLBCL RNA data from multiple organs, defined the new subtypes of adrenal gland DLBCL and explored their molecular signatures. The special expression pattern and microenvironment immunology scores of adrenal glands DLBCL were observed when compared with other organs. Natural killer T cells was predicted to significantly enrichment in adrenal gland DLBCL, canonical cancer pathways such as programmed death protein 1 signaling pathways, tumor necrosis factor signaling pathways and peptide antigen binding pathways were found to be correlated with adrenal gland DLBCL. Further analysis defined two distant adrenal gland DLBCL sub-type by RNA expression pattern. Our study revealed the special expression, defined the molecular subtype of adrenal gland DLBCL. These results expanded the organ related DLBCL data, provided the new knowledge of adrenal gland DLBCL expression profile.
MEMBER ACCOUNT
登录成功会直接打开下一页。